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Abstract Beneficial effects of glycyrrhizic acid (GA), a bioactive extract of licorice root, in the prevention of metabolic
syndrome have been consistently reported while advanced glycation end products (AGE) and receptor for advanced
glycation end product (RAGE) are the leading factors in the development of diabetes mellitus. The aim of this study was to
investigate the effects of GA on the AGE-RAGE axis using high-fat/high-sucrose (HF/HS) diet-induced metabolic syn-
drome rat models. Twenty four male Sprague–Dawley rats were randomly assigned into three groups for 4 weeks: (1)
Group A, normal diet with standard rat chow; (2) Group B, HF/HS diet; (3) Group C, HF/HS diet and oral administration of
100 mg/kg GA per day. The results showed that HF/HS diet elevated the fasting blood glucose level and insulin resistance
index which was prevented by GA supplementation. GA treatment significantly lowered the circulating AGE independent
of its glucose-lowering effect. HF/HS diet also triggered RAGE upregulation in the abdominal muscles while GA
administration downregulated RAGE expression in the abdominal muscles, aorta and subcutaneous adipose tissues. In
conclusion, HF/HS diet could cause glucose intolerance, insulin resistance and upregulation of RAGE expression while GA
ameliorated the metabolic dysregulation besides exhibiting inhibitory effects on the AGE-RAGE axis.
Keywords Metabolic syndrome  Receptor for advanced glycation end product  Licorice  High-fat/high-sucrose
diet
1 Introduction
Advanced glycation end product (AGE) is an irreversible
product resulted from non-enzymatic glycation of reducing
sugars like glucose and fructose to amino acid groups in
proteins and lipids, followed by the formation of Schiff’s
bases, Amadori products and eventually AGEs via a series
of rearrangement and oxidation reactions [1]. The glycation
pathway is known as Maillard reaction. Some of the most
abundant AGEs found in tissue proteins include N-e-(car-
boxymethyl)lysine, N-e-(carboxylethyl)lysine, pentosidine
and pyrraline. Aside from Maillard reaction, AGE forma-
tion can also be accelerated by other pathways, notably
glucose autooxidation, lipid peroxidation and polyol path-
way [2, 3].
Advanced glycation end product and the receptor for
advanced glycation end product (RAGE) are also increas-
ingly recognized as one of the leading factors to the onset
of diabetic vascular complications. In patients with type 2
diabetes mellitus, the level of circulating AGE was found
to have significantly escalated, implying that the rate of
glycation reaction is highly concentration-dependent [4].
The accumulated AGEs can interact with RAGE which
initiates multiple signaling cascades and subsequently
activates a regulatory protein for inflammatory and
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immune responses, nuclear factor-jB (NF-jB) [5]. This
links the AGE-RAGE axis to various pathological mani-
festations in the blood vessels such as proinflammation,
prothrombosis and increased leucocyte adhesion that con-
tribute to the development of endothelial dysfunction [1].
Moreover, RAGE expression is also upregulated by NF-jB
[6]. As a result, the entire RAGE-NF-jB inter-activation
becomes a self-perpetuating vicious cycle fuelled by AGE
ligand binding and transforms momentary inflammatory
response to an exaggerated form of sustained, chronic
inflammation at the endothelium [7].
Despite the AGE- and RAGE-facilitated diabetic vas-
cular injury, their roles and changes during the pre-diabetic
state or in metabolic syndrome are under-investigated. In
this context, metabolic syndrome has been the main
research focus of our laboratory. We have managed to
establish diet-induced metabolic syndrome rodent models
using high-fat diet [8], high-sucrose diet [9] and high-fat/
high-sucrose (HF/HS) diet [10]. The combined diet was
used in the present study as it is similar to the unhealthy
dietary pattern of people nowadays and hence, providing
higher magnitude of generalizability beyond the scope of
this study. While trying to understand the metabolic syn-
drome, we also actively seek for potential therapeutic
products from natural resources. One such bioactive com-
pound is glycyrrhizic acid (GA), which is a major con-
stituent found in the root of the genus Glycyrrhiza
(Leguminosae) or licorice plants. To elucidate, GA is a
non-selective inhibitor of 11b-hydroxysteroid dehydroge-
nase (11b-HSD) whose function is to catalyse the inter-
conversion of active and inactive glucocorticoids [11].
Inhibitory effect of GA on 11b-HSD type 1 isoform helps
to normalise the insulin sensitivity and the activity of
gluconeogenic enzymes which are otherwise, deranged by
the unhealthy diet [9]. In addition, GA is also a potent
agonist for peroxisome proliferator-activated receptor
(PPAR)-c [12, 13]. PPAR-c is markedly expressed in
adipocytes and is responsible for adipocyte differentiation
and lipid storage. GA-facilitated PPAR-c upregulation is
linked closely to improvements in glucose tolerance,
insulin sensitivity, lipid profile and ectopic lipid deposition
[12–14].
Considering the predominant roles of the AGE-RAGE
axis in the progression of diabetes mellitus, it seems per-
tinent to look at AGE accumulation and RAGE expression
in the early stage of the metabolic syndrome. Furthermore,
it is also of great research interest to examine the potential
inhibitory properties of GA on AGE and RAGE after
knowing the beneficial effects of GA on ameliorating
metabolic abnormalities. Thus, the objective of the present
study was to investigate the effects of orally-administered
GA on the AGE-RAGE axis of rats fed on HF/HS diet.
Aside from circulating AGE and RAGE expression in
multiple tissues, glucose tolerance and insulin sensitivity
were also assessed to give a better idea of the metabolic
state of the rats.
2 Results and Discussion
2.1 GA Prevented Diet-induced Glucose Intolerance
and Insulin Resistance
The mean fasting blood glucose levels (±SEM) of rats
from Groups A, B and C were 7.30 ± 0.62, 10.76 ± 1.30
and 6.66 ± 0.71 mmol/L respectively (Fig. 1a). The blood
glucose level of Group B rats was significantly higher than
that of the other two groups (p \ 0.05) whereas there was
no difference in blood glucose levels between Groups A
and C (p [ 0.05). This shows that consumption of HF/HS
diet elevated the circulating glucose, causing the rats to be
hyperglycaemic while oral administration of GA helped to
prevent the escalation and maintain the blood glucose
within the normal range. However, there was no statistical
significance in the mean HbA1c concentrations between
groups (p [ 0.05) (13.48 ± 1.95, 13.25 ± 1.15 and
16.32 ± 1.97 lg/mL for Groups A, B and C respectively)
(Fig. 1b). Similarly, there was also no significant differ-
ence in the AGE level between the groups on normal diet
and HF/HS diet (without GA treatment) (Fig. 2) even
though the fasting blood glucose of the rats feeding on HF/
HS diet was significantly higher. The inconsistencies sug-
gest that the diet-induced hyperglycaemia might not be
chronic enough to elevate HbA1c and circulating AGE
levels.
The mean fasting serum insulin concentrations (±SEM)
of rats from Groups A, B and C were 14.12 ± 0.92,
15.72 ± 0.59 and 12.01 ± 0.68 mU/L respectively
(Fig. 1c). There was no significant difference in the insulin
concentrations between groups (p [ 0.05) although the rats
on HF/HS diet appeared to have higher level of circulating
insulin than rats from the other two groups. HF/HS diet and
GA have substantial impacts on the development of insulin
resistance. Group B rats had the highest mean homeostatic
model assessment-insulin resistance (HOMA-IR) value
(±SEM), 8.00 ± 1.11 which was significantly higher than
that of Group A (4.61 ± 0.54) (p \ 0.05) and Group C
(3.50 ± 0.47) (p \ 0.01) (Fig. 1d). The high HOMA-IR
value indicates that rats on HF/HS diet for four weeks had
develop insulin resistance in comparison to those on a
normal diet. There was no difference in HOMA-IR indices
of Groups A and C rats (p [ 0.05).
The normal fasting blood glucose level of rats is com-
parable to that of humans, which ranges from approxi-
mately 5 to 7.5 mmol/L [15]. In this experiment, the
fasting blood glucose of the rats on only HF/HS diet was
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10.76 ± 1.30 mmol/L, indicating that the rats were hy-
perglycaemic. Although hyperinsulinaemia was not mani-
fested, the hyperglycaemic status was accompanied by
development of insulin resistance as evidenced by signifi-
cantly higher HOMA-IR when compared to the rats on
standard rat chow. This shows that the rats on HF/HS diet
are deemed adequate to be used as the metabolic syndrome
models for research purpose. The deleterious impacts of
unhealthy diet high in sucrose and/or saturated fat on
metabolism have been consistently reported not only in
animal studies [16–18] but also in clinical studies [19, 20].
The result of this study is in line with these studies.
By using GA as a supplement, the HF/HS diet-associ-
ated metabolic abnormalities were effectively prevented.
This observation is in concordance with the reported
findings from our laboratory which showed that GA
treatment could ameliorate metabolic symptoms like hy-
perglycaemia, insulin resistance and dyslipidemia in the
rats given high load of fat [8] and sucrose [9]. GA and its
derivatives are known to be PPAR-c agonists [21]. Chia
et al. [22] also revealed that oral administration of GA was
associated with upregulation of PPAR-c expression in the
VAT [22]. In the adipose tissues, PPAR-c activation is
crucial for adipogenesis by regulating expression of genes
which are involved in adipocyte proliferation and differ-
entiation as well as in fatty acid metabolism [23]. The
PPAR-c agonistic property of GA may play a key role in
restoration of the equilibrium between adipogenesis and
lipid influx and so, exerting modulatory effect onto the
development of adiposopathy or so-called ‘sick fat’.
In addition, GA is also known to be a non-selective 11b-
HSD inhibitor. In the liver, kidney, adipose tissues and
skeletal muscles, it has been demonstrated to inhibit the
activity of 11b-HSD type 1 whose function is to catalyse
the conversion of inactive glucocorticoid to the active form
[13]. By doing so, GA can inhibit the glucocorticoid-
induced signalling cascades, resulting in the reduction of
activity of the rate-limiting gluconeogenic enzyme, phos-
phoenolpyruate carboxykinase, in the liver and kidney [9].
This also shows that GA can exert effective modulation on
gluconeogenesis and restrict hepatic release of glucose into
the bloodstream.
Fig. 1 Mean (±SEM) a fasting blood glucose concentrations,
b HbA1c, c fasting serum insulin, d HOMA-IR of the rats in Groups
A, B and C at the end of the four-week treatment (*p \ 0.05 between
groups; **p \ 0.01 between groups). GA glycyrrhizic acid, HbA1c
glycated haemoglobin A1c, HF/HS high-fat/high-sucrose, HOMA-IR
homeostatic model assessment-insulin resistance
Novel Inhibitory Effects of Glycyrrhizic Acid 327
123
2.2 Novel AGE-lowering Effect of GA
GA treatment was able to reduce the level of AGE in the
blood stream. The serum AGE level (±SEM) of the rats on
GA was 19.90 ± 7.27 lg/mL, which was the lowest in
comparison to Groups A (63.95 ± 14.44 lg/mL) and B
(65.88 ± 18.10 lg/mL) rats (Fig. 2). The differences were
statistically significant between Groups A and C and
between Groups B and C (p \ 0.05), There was no sig-
nificant difference between the rats on normal diet and
those on HF/HS diet (p [ 0.05). Based on the results, it is
evident that GA could reduce the level of circulating AGE
significantly. This AGE-lowering effect of GA seems to be
independent from its anti-hyperglycaemic effect because
the GA-treated rats exhibited comparable fasting blood
glucose and HbA1c levels to those on normal diet. Previous
studies have reported that GA and its metabolites can
reduce early glycation products, intermediates in glycation
pathway and AGE [24, 25], but the inhibitory effects
cannot be differentiated from its glucose-lowering effect.
Therefore, the observation in the present study provides the
very first piece of evidence for AGE-lowering effect of GA
which is independent from its anti-hyperglycaemic effect.
In this context, it is postulated that GA may enhance the
efficiency of AGE detoxification and disposal. The under-
lying mechanism may be related to its ability to stimulate
PPAR-c expression and activation because some of the
PPAR-c agonists like pioglitazone and rosiglitazone under
the pharmacological class of thiazolidinedione have been
demonstrated to inhibit AGE accumulation in clinical
studies [26, 27]. Along with the decrease in AGE level, the
level of soluble RAGE (sRAGE) significantly increased
[26, 27]. A sRAGE is a circulating receptor for AGE which
is similar to the full-length membrane-bound RAGE
without the transmembrane and cytoplasmic signalling
domains [28]. The distinctive structure of sRAGE makes it
an excellent candidate as a decoy and a competitive
inhibitor for its membrane-bound isoform to scavenge
circulating AGEs and aid in AGE detoxification [29].The
PPAR-c agonistic properties of thiazolidinedione seems to
be closely associated to sRAGE level, suggesting a putative
regulatory role of PPAR-c on sRAGE expression. Hence,
since GA also possesses PPAR-c-activating characteristic,
it may inhibit AGE accumulation by enhancing scavenging
and clearance of AGEs through sRAGE upregulation.
2.3 GA Normalised Diet-induced RAGE
Overexpression
The relative RAGE expression ratios of Group B to Group
A rats in different tissues are shown in Fig. 3 in base 2 log
scale. RAGE expression (±SE) was upregulated in the
heart, aorta and subcutaneous adipose tissue (SAT) by
1.83 ± 0.90, 1.45 ± 1.31 and 2.12 ± 1.35 fold respec-
tively, and was downregulated in the liver, kidney, quad-
riceps femoris (QF) and visceral adipose tissue (VAT) by
2.22 ± 0.29, 1.65 ± 0.92, 2.03 ± 0.26 and 2.75 ± 0.27
fold respectively. However, these differences in RAGE
expression did not reach statistical significance (p [ 0.05).
























Fig. 2 Mean serum AGE concentrations (±SEM) of rats in Groups A, B and C at the end of the four-week treatment (*p \ 0.05 between
groups). GA glycyrrhizic acid, HF/HS high-fat/high-sucrose
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RAGE of the rats on HF/HS diet was significantly upreg-
ulated by 6.78 ± 5.33 fold compared to those on normal
diet (p \ 0.01).
In contrast, when comparing the rats with and without
GA treatment, the RAGE expression of Groups C to B rats
was significantly downregulated in the aorta, AM and SAT
by 4.16 ± 0.17 fold (p \ 0.05), 7.86 ± 0.085 fold
(p \ 0.01) and 5.72 ± 0.12 fold respectively (p \ 0.05).
The expression was also downregulated in the kidney and
heart by 1.74 ± 0.72 and 1.74 ± 0.32 fold respectively but
the changes did not reach statistical significance
(p [ 0.05). Conversely, GA-treated rats had their RAGE
expression upregulated in the liver, QF and VAT by
1.07 ± 0.51, 2.41 ± 1.43 and 1.95 ± 1.84 fold respec-
tively. The upregulated RAGE expression in the three tis-
sues was not statistically significant (p [ 0.05). The
relative RAGE expression of Groups C to B rats is illus-
trated in Fig. 4.
Downregulation of RAGE expression was observed in
most tissues of Group C rats in comparison to Group A rat
except for the heart and QF where the gene was upregulated
by 1.09 ± 0.49 and 1.53 ± 0.47 fold respectively. RAGE
expression was downregulated by 2.00 ± 0.30 fold in the
liver, 2.97 ± 0.47 fold in the kidney, 2.83 ± 0.28 fold in the
aorta, 1.15 ± 0.41 fold in AM, 2.87 ± 0.23 fold in SAT and
1.58 ± 0.47 fold in VAT. Yet, all of the gene regulation did
not reach statistical significance (p [ 0.05), indicating that
the RAGE expression of the rats on HF/HS diet with GA
treatment did not differ from those on standard rat chow. An
illustration of the relative gene expression of Groups C to A
rats is shown in Fig. 5.
Generally, RAGE expression was unaffected in some
tissues such as the liver, kidney, heart and VAT. This
again, supports the postulation that the diet-induced met-
abolic abnormalities were not chronic enough to trigger
significant derangements in the AGE-RAGE axis. What is
surprising is that the RAGE expression of the rats on only
HF/HS diet was significantly upregulated in AM as com-
pared to the rats on standard rat chow even when the two
groups of rats exhibited similar level of circulating AGE
level. This is attributable to the multiligand functionality of
RAGE. Aside from AGE, RAGE is also known to interact
with HMGB1 [30] and S100 protein family [31]. Empirical
findings demonstrated that these ligands are also overex-
pressed and secreted in metabolically-deranged rats [32,










































Fig. 3 Relative expression ratios (±SE) of RAGE in different tissues
in base 2 log scale using BAC as the endogenous reference, Group A
(rats on standard rat chow) as the calibrator and Group B (rats on HF/
HS diet) as the target (**p \ 0.01 between groups). The data labels
indicate the actual relative expression ratios (in fold) with positive
values denoting upregulation while negative values denoting down-
regulation. L liver, K kidney, H heart, A aorta, AM abdominal muscle,
QF quadriceps femoris, SAT subcutaneous adipose tissue, VAT
visceral adipose tissue
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triggered resultant signalling cascades and the RAGE
overexpression in the AM. Increased RAGE mediated-
signalling cascades in the skeletal muscles is linked to pro-
inflammation and high oxidative stress [34]. Furthermore,
Cassese et al. [35] revealed that RAGE may interact with
Src tyrosine kinase, PKC-a and IRS-1 to form a multi-
molecular complex which desensitises insulin action in the
skeletal muscles and causes muscular insulin resistance
[35]. As skeletal muscles are the primary sink for insulin-
stimulated glucose disposal, the development of muscular
insulin resistance may lead to high circulating glucose
retention and glucose intolerance.
The upregulation of RAGE caused by HF/HS diet were
effectively prevented by GA treatment as evidenced by the
significant downregulation in the aorta, AM and SAT. The
downregulation was paralleled with the reduction in the cir-
culating AGEs. This indicates that the AGE-lowering effect of
GA might have hindered the RAGE activation. The multili-
gand functionality of RAGE also suggests multiple inhibitory
effects of GA on other ligands. Indeed, GA can inhibit
HMGB1 secretion, resulting in the reduction of a series of
inflammatory and oxidative markers in a dose-dependent
manner [36]. These inhibitory properties of GA on different
RAGE ligands may effectively prevent diet-induced RAGE
activation and overexpression which then help to attenuate the
progression of cellular injury due to metabolic derangements.
Although GA treatment could lower serum AGE level and
impede the diet-induced upregulation of RAGE, it did not
abolish the basal expression of RAGE. This is reflected in the
observation that the rats on normal diet and the rats on HF/HS
diet and GA treatment shared comparable RAGE expression
across all the studied tissues. This is essential as the physio-
logical functions of RAGE, which is associated with inflam-
matory response and innate immunity [37], may be preserved
despite the GA treatment.
3 Experimental Section
3.1 Source of the Natural Product
Ready-to-use GA ammonium salt from Glycyrrhiza root
(licorice) was purchased in solid powder form from Sigma–
Aldrich (Selangor, Malaysia). The compound is extracted by
HPLC. The product number is G2137. More information










































Fig. 4 Relative expression ratios (±SE) of RAGE in different tissues
in base 2 log scale using BAC as the endogenous reference, Group B
(rats on HF/HS diet) as the calibrator and Group C (rats on HF/HS
diet and GA) as the target (*p \ 0.05, **p \ 0.01 between groups).
The data labels indicate the actual relative expression ratios (in fold)
with positive values denoting upregulation while negative values
denoting downregulation. L liver, K kidney, H heart, A aorta, AM
abdominal muscle, QF quadriceps femoris, SAT subcutaneous adipose
tissue, VAT visceral adipose tissue
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3.2 General Experimental Procedures
The rats were obtained from the Monash University Animal
Facility unit. Standard rat chow, coarse granulated cane
sugar and ghee were purchased from Gold Coin, Malayan
Sugar Manufacturing and Michelle Foods Sdn. Bhd. whose
companies are all based in Malaysia. Glucose oxidase and
peroxidase used in Trinder’s glucose oxidase test were pur-
chased from Sigma–Aldrich (Selangor, Malaysia). Rat/
Mouse Insulin ELISA kit was purchased from Millipore
(Selangor, Malaysia). Rat Glycated Haemoglobin A1c
(GHbA1c) ELISA Kit was purchased from CUSABIO
(Wuhan, China) while OxiSelectTM Advanced Glycation
End Product (AGE) ELISA Kit was acquired from Cell
Biolabs (Selangor, Malaysia). Total RNA extraction kit such
as Qiagen RNeasy Mini Kit, Qiagen RNeasy Lipid Tissue
Mini Kit and Qiagen Omniscript Reverse Transcription kit
were obtained from Qiagen (Kuala Lumpur, Malaysia).
3.3 Animal Sampling and Treatment
The use and handling of animals in the research project have
been approved by Monash University School of Biomedical
Sciences Animal Ethics Committee (AEC Approval Num-
ber: MARP/2012/043). All applicable institutional and/or
national guidelines for the care and use of animals were
followed. Twenty four male, eight-week old Sprague–
Dawley rats (Rattus norvegicus) with an initial weight of
around 160–200 g were obtained. Throughout the entire
experiment, the rats were kept individually in polypropylene
cages with paper bedding at 23 ± 1 C and 12-hour-light-
and-dark exposure (lights on at 0600 and lights out at 1800).
Prior to treatment, the rats were acclimatized for 1 week to
allow them to adapt to the laboratory conditions. During that
time, they were given standard rat chow and tap water. After
the acclimatization, the rats were randomised into three
groups: groups A, B and C (n = 8 per group). Group A rats
were provided standard rat chow while Groups B and C rats
were on/diet (30 % ghee and 30 % sugar). The HF/HS diet
was prepared by evenly mixing powdered standard rat chow,
coarse granulated cane sugar and ghee in a ratio of 4:3:3
respectively. The mixture was then baked for 10 min at
160 C and stored at 4 C in a fridge until use. The thera-
peutic intervention, 100 mg/kg GA was subjected exclu-
sively for group C rats via oral administration in drinking







































Fig. 5 Relative expression ratios (±SE) of RAGE in different tissues
in base 2 log scale using BAC as the endogenous reference, Group A
(rats on standard rat chow) as the calibrator and Group C (rats on HF/
HS diet and GA) as the target. The data labels indicate the actual
relative expression ratios (in fold) with positive values denoting
upregulation while negative values denoting downregulation. L liver,
K kidney, H heart, A aorta, AM abdominal muscle, QF quadriceps
femoris, SAT subcutaneous adipose tissue, VAT visceral adipose tissue
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3.4 Sample Collection
After the treatment period had completed, the rats were
subjected to 8 h fasting before being humanely sacrificed
under the effects of 75 mg/kg of ketamine and 10 mg/kg of
xylazine hydrochloride via intraperitoneal injection. Whole
blood, red blood cell lysate and serum were collected. Red
blood cell lysate and serum were stored at -80 C until
further use. The liver, kidney, aorta, heart, AM, QF, SAT
and VAT were harvested promptly, snap frozen in liquid
nitrogen and stored at -80 C.
3.5 Biochemical Tests
Blood glucose was measured using Trinder’s glucose oxi-
dase test while serum insulin was determined using based
Rat/Mouse Insulin ELISA Kit. To quantify insulin resis-
tance, HOMA-IR was computed based on the fasting blood
glucose and fasting insulin levels according to the formula
as shown [39].
HbA1c concentrations were determined using competitive-
based Rat Glycated Haemoglobin A1c (GHbA1c) ELISA
Kit. Serum AGE levels were measured using OxiSelectTM
Advanced Glycation End Product (AGE) ELISA Kit.
3.6 RNA Extraction and cDNA Synthesis
Total RNA was extracted from the liver, kidney, heart,
aorta, AM and QF using the Qiagen RNeasy Mini Kit while
that of the SAT and VAT were isolated using the Qiagen
RNeasy Lipid Tissue Mini Kit. The concentration and
purity of the extracted RNA was checked by measuring the
absorbance at 260 and 280 nm. RNA integrity was asses-
sed using agarose gel electrophoresis. RNase-free DNase
treatment was carried out using Fermentas DNase I RNase-
free (Fermentas, Malaysia) to avoid genomic DNA con-
tamination. RNA extracts were then used as the template
for cDNA synthesis with Qiagen Omniscript Reverse
Transcription kit.
3.7 Quantitative RT-PCR of RAGE
Rotor-Gene Q (Qiagen, USA) was used for qRT-PCR.
RAGE was the gene of interest while b-actin gene (BAC)
was the chosen endogenous housekeeping gene for nor-
malization of the gene of interest during comparison. The
primers and probes are outlined in Table 1. The compari-
sons of RAGE expression between groups were performed
using Relative Expression Software Tool for Rotor-Gene
3000 and 6000 (REST-RG) Version 3. Agarose gel
electrophoresis was carried out to confirm the specificity of
the qRT-PCR products.
3.8 Statistical Analysis
All data were processed and analysed using Statistical
Package for the Social Sciences (SPSS) Version 20.0
except relative expressions for RAGE which were analysed
using REST-RG Version 3. For parametric data, one-way
ANOVA was used to make comparisons between groups
followed by Post Hoc (Tukey) test while for non-para-
metric data, Kruskal–Wallis test was used followed by
Mann–Whitney U test. To analyse the relative expressions
of RAGE, take-off points and PCR reaction efficiencies of
each sample were imported from ‘Comparative Quantita-
tion’ feature of Rotor-Gene Q into the REST-RG Version
3 where the expression ratios of target (treatment group) to
calibrator (control group) were calculated. For all data
analyses, a p value of B 0.05 was considered statistically
significant.
4 Conclusion
In consistence with previous findings reported by Chand-
ramouli et al. [9], HF/HS diet could lead to impaired
Table 1 Nucleotide sequences of RAGE and BAC primers and
probes
Primer/probe Nucleotide sequence (50 ? 30)
RAGE forward
primer
CCC TGA CCT GTG CCA TCT CT
RAGE reverse
primer
GGG TGT GCC ATC TTT TAT CCA




GTA TGG GTC AGA AGG ACT CC
BAC reverse
primer
GTT CAA TGG GGT ACT TCA GG
BAC probe [TET] CCT CTC TTG CTC TGG GC [BHQ1]
HOMA  IR ¼ Fasting blood glucose ðmmol=LÞ  Fasting serum insulin ðmU=LÞ
22:5
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glucose tolerance and insulin resistance which were
effectively prevented by GA treatment at a dosage of
100 mg/kg/day. GA treatment could also significantly
reduce circulating AGEs by a mechanism which was
believed to be independent from its anti-hyperglycaemic
effect. Furthermore, HF/HS diet triggered significant
RAGE overexpression in the AM. RAGE upregulation
which did not reach statistical significance was also
detected in the heart, aorta and SAT. GA treatment man-
aged to prevent the diet-induced RAGE expression dys-
regulation in the aorta, AM and SAT without jeopardising
the basal expression in all the studied tissues. Thus, GA can
effectively offset the negative impacts on the metabolism
caused by HF/HS diet. Its inhibitory effects on the AGE-
RAGE axis also make it a potential treatment for diabetic
vascular diseases aside from being a preventive drug for
the metabolic syndrome.
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